REDWOOD CITY, Calif.--(BUSINESS WIRE)--Tranquis Therapeutics, a private immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases by reprogramming dysfunctional myeloid immune cells, today announced it has strengthened its management team with the addition of Faisal Shawwa, MBA, as Senior Vice President of Finance and Administration and Janet Hurt, MPH, as Senior Vice President of Clinical Evidence Generation. Mr. Shawwa and Ms. Hurt will be members of Tranquis’ Executive Leadership Team.
“The expansion of our highly experienced team has led to the effective translation of our preclinical work and enabled our lead program TQS-168 to enter the clinic. We are excited about the continued progress in our discovery work and our focus on building the team and infrastructure necessary to advance therapeutic programs into the clinic,” said Frederic Godderis, COO of Tranquis. “In 2022, we anticipate building on this momentum, making significant clinical progress with TQS-168, advancing our pipeline and expanding our discovery platform. We’re thrilled to have industry leaders like Janet and Faisal join as we continue our growth, and their combined track records will suit us very well moving forward.”
Janet Hurt brings 30 years of early and late-stage clinical development expertise to Tranquis. Most recently, she served as Vice President of Clinical Operations at Jasper Therapeutics where she established and led the clinical operations function, which included clinical data management and clinical outsourcing. Prior to Jasper, Janet has led clinical operations, clinical data management and clinical outsourcing at several biopharmaceutical companies including Denali Therapeutics, Onyx, Bavarian Nordic, XenoPort, and Amgen. Janet received her MPH and BS from San Jose State University.
Faisal Shawwa has over 25 years of experience and an established track record of building and leading finance, accounting, administration, IT, facilities, external reporting and compliance functions. Throughout his career, he has successfully led and supported the completion of multiple rounds of funding to advance R&D programs, acquisitions, partnerships, and commercial launches. Most recently he was VP of Finance for Catalyst Biosciences, a publicly traded biopharmaceutical R&D company. Faisal was responsible for guiding the financial transformation of the company and led Catalyst’s successful initial public offering and follow-on financings. Prior to his role at Catalyst, he held finance leadership positions of Corporate Controller and Principal Accounting Officer for Preferred Financial Group and as the Head of Finance and Accounting for Provident Funding. Faisal received his MBA in finance and BS in business administration from Notre Dame Graduate School of Business.
About Tranquis
Tranquis Therapeutics is a breakthrough biopharmaceutical company focused on developing a portfolio of promising small molecule drugs with a unique mechanism of action, capable of reprogramming dysfunctional myeloid immune cells to revolutionize the management of a broad range of mitochondrial and immune mediated CNS and non-CNS indications and to significantly improve the lives of millions of patients. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapies work by restoring normal mitochondrial biogenesis, cell homeostasis and function, effectively “switching” microglia and monocytes from a dysfunctional to a functional state by targeting master regulators of cell energy metabolism. For more information, visit www.tranquis.com.
